BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 24565990)

  • 1. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
    Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
    Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.
    Utsunomiya A; Miyazaki Y; Takatsuka Y; Hanada S; Uozumi K; Yashiki S; Tara M; Kawano F; Saburi Y; Kikuchi H; Hara M; Sao H; Morishima Y; Kodera Y; Sonoda S; Tomonaga M
    Bone Marrow Transplant; 2001 Jan; 27(1):15-20. PubMed ID: 11244433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
    Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
    Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
    Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Tanaka J; Kanamori H; Nishiwaki S; Ohashi K; Taniguchi S; Eto T; Nakamae H; Minagawa K; Miyamura K; Sakamaki H; Morishima Y; Kato K; Suzuki R; Nishimoto N; Oba K; Masauzi N
    Bone Marrow Transplant; 2013 Nov; 48(11):1389-94. PubMed ID: 23665820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
    Itonaga H; Taguchi J; Fukushima T; Tsushima H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Honda S; Miyazaki Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):607-15. PubMed ID: 23333533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
    Shiratori S; Yasumoto A; Tanaka J; Shigematsu A; Yamamoto S; Nishio M; Hashino S; Morita R; Takahata M; Onozawa M; Kahata K; Kondo T; Ota S; Wakasa K; Sugita J; Koike T; Asaka M; Kasai M; Imamura M
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):817-23. PubMed ID: 18541202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Tokunaga M; Uto H; Takeuchi S; Nakano N; Kubota A; Tokunaga M; Takatsuka Y; Seto M; Ido A; Utsunomiya A
    Leuk Lymphoma; 2017 Jan; 58(1):37-44. PubMed ID: 27654808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden.
    Zhang WP; Yang D; Song XM; Ni X; Chen J; Chen L; Yang JM; Zhou H; Cheng H; Liu BH; Li HM; Wang JM
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):653-60. PubMed ID: 23353118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.